MGTX Meiragtx Holdings Plc

MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.

$17.95  -0.93 (-4.93%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Cayman Islands
IPO date:  06/08/2018
Outstanding shares:  44,448,624
Average volume:  250,913
Market cap:   $839,190,021
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    G59665102
ISIN:        KYG596651029
Sedol:      BFYQFJ2
Valuation   (See tab for details)
PE ratio:   -9.96
PB ratio:   4.23
PS ratio:   41.04
Return on equity:   -37.08%
Net income %:   -340.70%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy